

## CURRICULUM VITAE

**Danxin Wang, MD, PhD**

### OFFICE ADDRESS

Associate Professor  
Department of Pharmacotherapy and Translational Research  
College of Pharmacy  
University of Florida  
MSB Room PG-05B  
1345 Center Drive  
PO Box 100486  
Gainesville, FL 32610  
Tel: 352-273-7673  
Email: danxin.wang@cop.ufl.edu

### EDUCATION

1985 M.D Fudan University Medical School, Shanghai, China  
1988 M.S Fudan University Medical School, Shanghai, China (Pharmacology)  
1991 Ph.D Academy of Military Medical Sciences, Beijing, China (Pharmacology)

### INTERNSHIP AND FELLOWSHIP

1984-1985 Intern, Internal Medicine, Xuhui Center Hospital, Shanghai, China  
1996-1999 Postdoctoral Fellow, University of California San Francisco, San Francisco, California

### ACADEMIC APPOINTMENTS

1991-1996 Assistant Professor, Academic of Medical Sciences, Beijing, China  
1996-2001 Postgraduate Researcher, Department of Biopharmaceutical Sciences, College of Pharmacy, University of California San Francisco, San Francisco, California  
2001-2002 Specialist, Department of Biopharmaceutical Sciences, College of Pharmacy, University of California San Francisco, San Francisco, California  
2002-2010 Research Scientist/Adjunct Assistant Professor, Department of Pharmacology, College of Medicine, The Ohio State University, Columbus, Ohio  
2010-2018 Research Scientist/Adjunct Associate Professor, Department of Pharmacology, College of Medicine, The Ohio State University,  
2010-2018 Associate Director, Center for Pharmacogenomics, School of Medicine, The Ohio State University, Columbus, Ohio  
2016-2017 Research Scientist, Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, Ohio  
2017- 2018 Research Assistant Professor, Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, Ohio  
2018- Associate Professor, Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida

### OTHER APPOINTMENTS

2017-2018 Expert advisor for ChromoCare, a biomarker company, Columbus, Ohio

### HONOR AND AWARDS

2019 Featured Investigator, Pharmacogenomics Research Network (PGRN)  
2014 Featured Investigator, Pharmacogenomics Research Network (PGRN)  
1996 INVEST Research Fellowship, National Institute on Drug Abuse, NIH  
1985 Shi Li Yue-Qing Scholarship, Fudan University Medical School, Shanghai, China

## TEACHING

### Courses

#### The Ohio State University

##### Instructor

2014-2018 BSGP8800.05: Genomic Medicine and Pharmacogenomics  
2014-2017 Pharm 5700: Pharmacogenomics and Personalized Medicine  
2010-2014 Pharm725: Pharmacogenomics

#### University of Florida

##### Course coordinator and Instructor

2018-2020 PHA 6134: Foundations in Precision Medicine--Genomic Technologies  
2020-2021 PHA 6935: Foundations in Precision Medicine—Principles of Pharmacogenomics and Genomic Technologies  
2021- PHA 6427: Pharmacogenetics of Drug Metabolism and Transport

##### Instructor

2019 PHA6427: Pharmacogenetics  
2019- PHA5907: Research in Pharmacy Practice  
2020- PHA5930: Seminars in Pharmacy Research  
2022- PHA 6449: Pharmacogenomic and Genomic Data Analysis

### Dissertation Committee

Guang Yang	2018-2020	Member
L. Manasa S. Chekka	2018-2021	Member
Mohammed Gbadamosi	2018-2021	Member
Christelle Lteif	2018-2021	Member
Noor A. Nahid	2019-2023	Member
Abelardo D. Montalvo	2021-	Chair

### Students/Trainees

#### Undergraduate research Mentor

2018-2019 Tina Chen  
2020-2020 Lucas Zhou

#### PharmD student research mentor

2019-2020 Abelardo Montalvo  
2020- Adaeze C. Nworu  
2020- Lucas Zhou  
2021-2022 Joseph Atia  
2021-2022 Jung Lee  
2021 Yaima Jimenez Hernandez  
2022 Rebecca Lynn Laguerre

#### PostDoc mentor

2018- Joseph M. Collins  
2021 Marwa Tantawy

#### Laboratory Personnel

2017-2018 Lynda Stauffer  
2018-2020 Dahao Ling  
2022- Hannah Lester

PharmD student Faculty advisor

2019- Alan Conrad  
2019- Kathryn Hauser  
2019- Rebecca Laguerre  
2019- Evangelia Manias  
2019- Gino Tornese

## **SERVICE**

### ***University Wide***

2018- Research Committee, School of Pharmacy, University of Florida  
2019 Faculty Search committee, Department of Pharmacotherapy and Translational research  
School of Pharmacy, University of Florida  
2019- Research Showcase Judge, School of Pharmacy, University of Florida  
2021 Faculty Search committee, Department of Pharmacotherapy and Translational research  
School of Pharmacy, University of Florida  
2022 Department Chair Search committee, Department of Pharmacodynamics, University of Florida

### ***National/International***

#### **Grant Review**

2/15/2018 National Institute on Drug Abuse Special Emphasis Panel (ZDA1 HX)-H (15) study section:  
Pharmacogenomics of Anti-retroviral Therapy in People Who Inject Drugs (R01)

3/25/2021 National Institutes of Health Center for Scientific Review Special Emphasis Panel ZRG1  
EMNR-G 02S: Topics in Reproduction, Endocrinology and Metabolism (R01)

4/20/2021 National Institutes of Health Eunice Kennedy-Shriver National Institutes of Child health and  
Human Development Maternal and Pediatric Precision in Therapeutics (MPRINT) Centers of Excellence  
in Therapeutics RFA-HD-21-026 (P50)

3/24/2022 National Institute of Health Center for Scientific Review Special Emphasis Panel: Pediatric  
and Obstetric Pharmacology and Therapeutics ZRG1 EMNRS (55) R

#### **Professional Organizations**

2019- NIH-funded Pharmacogenetic Variation Consortium (PharmVar) CYP3A4 expert panel  
2019 Organizing Committee Member  
International Conference on Molecular Biology and Genetic Engineering, Nov., 2019  
2020 Scientific Committee Member  
International 2<sup>nd</sup> Pharmaceuticals Pharmacology and Drug delivery Systems, July, 2020  
2020 Mentor, Human Genetics Scholar Initiative, American Society of Human Genetics (ASHG)  
2021 Proposal reviewer, American Society for Clinical Pharmacology and Therapeutics (ASCPT)  
2020 American Association of Colleges of Pharmacy (AACP)

#### **Editorial Board**

2010-2011 Associate editor of 'European Journal of Pharmaceutical Sciences'  
2010-2015 Member of Editorial Board of 'Journal of Pharmacogenomics and Pharmacoproteomics'  
2019- Member of Editorial Board of 'Pharmacology: Drug action Study Journal'

#### **Journal Article Reviewer**

Basic and Clinical Pharmacology and Toxicology  
Current Pharmacogenomics and Personalized Medicine  
European Journal of Pharmaceutical Sciences  
Frontiers  
Gene  
Genetics and Molecular Biology  
Human Mutation

Journal of Pharmacogenomics and Pharmacoproteomics  
Molecular Diagnosis and Therapy  
Pharmacogenomics  
Scientific report  
The Pharmacogenomics Journal  
Thrombosis and Hemostasis  
Journal of Thrombosis and Thrombolysis  
PLOS  
Molecular Biology Reports  
Genetic Testing and Molecular Biomarkers

### **Other**

2020- Judge for ASHG DNA day essay

### **PROFESSIONAL AFFILIATIONS**

Member of Pharmacogenomics Research Network (PGRN)  
Member of American Society of Pharmacology Experimental Therapeutics (ASPET)  
Member of International Society for Neurochemistry (ISN)  
Member of International Society for the Study of Xenobiotics (ISSX)  
Member of Society for Neurosciences (SFN)  
Member of International Narcotic Research Conference (INRC)  
Member of NIH-funded Pharmacogenetic Variation Consortium (PharmVar)  
The American Society of Human Genetics (ASHG)  
Member of American Society for Clinical Pharmacology and Therapeutics (ASCPT)

### **PROFESSIONAL DEVELOPMENT**

2021 Microsoft Teams COP Faculty Training  
2021 Implicit Bias Training for Pharmacy School Interviews  
2021 Multicultural Mentoring  
2020 Team Science Academy: Science of Team Science  
2020 Edge for Scholars member  
2020 Professional Development Seminar series: learn, discovery and lead  
2019 Master Mentor, Mentor Academy, University of Florida

### **RESEARCH GRANTS**

#### **Funded**

**R35 Maximizing Investigators' Research Award (MIRA) GM140845** (PI: Danxin Wang)

04/01/2021-01/31/2026

Title: Expression genetics of Pharmacogenes

Role: **Principle Investigator**

**R01 GM120396** (PI: Danxin Wang) 04/01/2017-03/31/2021 no cost extension to 2022

Title: Expression genetics of CYP3A drug metabolizing enzymes

Role: **Principle Investigator**

**R01 sub-award project P0091589** 05/01/2019-04/30/2022

Sub-contract from The Ohio State University (R01 MD011307, PI: Sakima Smith)

Title: Translational candidate-gene studies of simvastatin-induced myopathy in African Americans

Role: **Principle Investigator**

**2020 Research opportunity seed Fund, University of Florida (PI: Sophia Skeikh)**

07/01/2020-06/30/2022

Title: Geospatial Analysis to predict pain outcomes

Role: **Co-investigator**

### Completed Research Support

**R01 sub-award project P0103461** 02/01/2016-01/31/2021  
Sub-contract from University of Michigan (R01 HL126969, PI: Haojie Zhu)  
Title: Genetic determinants of ACE1 prodrug activation  
Role: **Principle Investigator**

**R01 MD011307 (PI: Kitzmiller)** 10/01/2017-04/30/2019  
Title: Translational candidate-gene studies of simvastatin-induced myopathy in African Americans  
Role: **Co-Investigator**

**R000 Takeda Pharmaceuticals International, Inc. (PI: Wolfgang Sadee)** 01/01/2015-12/31/2017  
Title: Molecular genetics and genomics of Lurasidone  
Role: **Co-Investigator**

**U01 GM092655 (PI: Wolfgang Sadee)** 07/2010-06/2015  
Title: Expression genetics in drug therapy  
Role: **Co-Investigator**

**U01 GRT00016471 (PI: Wolfgang Sadee)** 08/2010-7/31/2015  
Sub-contract from University of Florida (U01, PI: Julie Johnson)  
Title: Pharmacogenomics evaluation of antihypertensive response  
Role: **Co-Investigator**

**R000 Takeda Pharmaceuticals International, Inc. (PI: Wolfgang Sadee)** 01/01/2014-12/31/2014  
Title: Molecular genetics and genomics of Vortioxetine (Brintellix)  
Role: **Co-Investigator**

**R21 AI074399** 06/01/2008 -05/31/2011  
Title: Pharmacogenetics of sulfamethoxazole in HIV/AIDS patients  
Role: **Principle Investigator**

**R000 Eli Lilly & Co. (PI: Wolfgang Sadee)** 09/2007-08/2009  
Title: Quantitative assessment of regulatory polymorphisms in CYP3A4  
Role: **Co-Investigator**

### Unfunded proposals

**R01 DA051422 (PI: Danxin Wang)** 07/01/2020-06/30/2015  
Title: Improving CYP2D6 genetic testing panel for personalized opioid therapy

### **UNITED STATE PATENT APPLICATIONS**

Neutral Antagonists and use thereof in treating drug abuse. Inventors: Wolfgang Sadee and Danxin Wang, Patent No. 20030069262, 20010049375, **granted in 2004**

Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof. Inventors: Wolfgang Sadee and Danxin Wang. PCT/US08/086939, 2008

Polymorphisms in genes affecting CNS disorders and uses thereof. Inventors: Wolfgang Sadee, Danxin Wang, et al. PCT/US2007/75010 Int'l filing date: Aug 1, 2007, WO 2008/017002 A2

Polymorphisms in genes affecting CYP2C9 related disorders and uses thereof. Inventors: Wolfgang Sadee and Danxin Wang PCT/US08/005539, May 27, 2010

Assessing CYP3A4 metabolizer status using CYP3A4/CYP3A5 genotyping panel. Inventor: Wolfgang Sadee and Danxin Wang. Patent # US 9938576 B1, **granted in 2018, licensed Mayo Foundation for Medical Education and Research A2012-0967**

Regulatory CYP2D6 polymorphisms affecting splicing and transcription as pharmacogenetic biomarkers defining CYP2D6 metabolizer status. Inventor: Danxin Wang and Wolfgang Sadee, application #14/064,385, 2013

Polymorphisms in genes affecting ACE-related disorders and uses thereof. Inventors: Wolfgang Sadee, Andrew D. Johnson, Danxin Wang, Audrey C. Papp US9012143B2, 2015

Method for predicting statin response: combination of two CYP7A1 variants. Inventors: Danxin Wang, Wolfgang Sadee, 2017, ref# 10336-445PV1

## INVITED SYMPOSIUM

- 2005 **Allele specific expression and splice variants of L-type calcium channel alpha subunit, CACNA1C.** Invited by Julie Johnson, Pharm D, School of Pharmacy, Center for Pharmacogenomics, University of Florida. Dec. 12-13, 2005
- 2007 **Identifying genetics biomarkers for personalized prescription.** Department of Pharmacology Research Day, The Ohio State University, March 26, 2007
- 2009 **Identifying functional polymorphism in CYP3A4 that affects hepatic expression and response to statin drugs.** Molecular Diagnostics World Congress, South San Francisco Conference Center, CA, August 6-7, 2009
- 2009 **Discovery of genetic biomarker for drug response and dosage.** Personalized Healthcare National Conference Pharmacogenomics Workshop, The Ohio State University, Columbus, October 1-2, 2009
- 2010 **Identify genetic contributors for sulfamethoxazole induced adverse drug reactions in HIV/AIDS patients,** Department of Pharmacology Seminar, The Ohio State University, 2010
- 2010 **Structure RNA polymorphisms (srRNAs) affecting RNA processing and translation.** 40<sup>th</sup> Annual Gordon Research Conference on Drug Metabolism, Holderness School, New Hampshire, July 11-16, 2010
- 2011 **Genetics of idiosyncratic drug reactions—sulfamethoxazole induced hypersensitivity in HIV/AIDS patients.** Pharmacogenomics Research Network Research in Progress webinar. Jan 14, 2011
- 2011 **Identifying functional regulatory polymorphisms for personalized drug therapy.** Invited by Hyunyoung Jeong, Ph.D, PharmD, School of Pharmacy, University of Illinois at Chicago. March 2, 2011
- 2012 **Polymorphisms affecting CYP2D6 expression: Regulation by splicing and distal enhancers. New biomarkers for CYP2D6 activity.** Pharmacogenetics Research Network Meeting, Seattle, WA, October 2012
- 2012 **Novel cis-acting regulatory polymorphisms in cytochrome P450 2D6 and its clinical Implications.** The Ohio State University Integrated Biomedical Graduate Program 7991, Columbus, OH, November, 2012
- 2016 **CYP enzymes, the CYP3A regulome.** Precision Medicine. Columbus, Ohio, February 7, 2016
- 2019 **Functional Annotation of Genetics variants.** University of Michigan, Feb. 2019
- 2019 **Role of unliganded estrogen receptor alpha (ESR1) in cytochrome P450 drug metabolizing enzymes gene expression regulation.** PGRN Research in Progress, September, 2019
- 2020 **Experimental approach to functionally annotate genetic variants.** University of Michigan School of Pharmacy, March 2020
- 2020 **Regulatory polymorphisms in drug metabolizing enzymes and their clinical relevance.** Oral presentation, Virtual online conference on Pharmaceutics, Pharmacology and Drug Delivery Systems, September, 10, 2020

## PUBLICATIONS

### Peer reviewed articles

89 peer-reviewed publications overall, H-index: 40 by Google Scholar; 35 by Scopus; 38.94 by Research Gate

- (1) C. Rodriguez-Antona, J.L Savieo, V.M. Lauschke, K. Sangkuhl, B.I. Drogemoller, **D. Wang**, R.H.N. van Schaik, A. A. Gilep, A.P. Peter, E.C. Boone, B.E. Ramey, T.E. Klein, M. Whirl-Carrillo, V.M. Pratt and A. Gaedigk. PharmVar GeneFocus: CYP3A5. Clin Pharmacol Ther. 2022, in press, PMID: 35202484
- (2) J.M. Collins, R. Lu, X. Wang, H.J. Zhu and **D. Wang**. Transcriptional regulation of carboxylesterase 1 in human liver: role of the nuclear receptor subfamily 1 group H member3 and its splice isoforms. Drug Metab Dispos. 50:43-48, 2022. PMID: 34697082
- (3) J.M. Collins and **D. Wang**. Cytochrome P450 3A4 (CYP3A4) protein quantification using capillary western blot technology and total protein normalization. J Pharmacol Toxicol Methods. 112:107117, 2021. PMID 34474151, DOI: [10.1016/j.vascn.2021.107117](https://doi.org/10.1016/j.vascn.2021.107117)
- (4) G. Yang, S. Singh, C. McDonough, J. Lamba, I. Hamadeh, L. S. Holliday, **D. Wang**, T. Langaee, J. Katz, P. Lakatos, B. Balla, J. Kosa, S. V. Driest, D. Price, W. Figg, G. Pelliccioni, J. Moreb and Y. Gong. Genome-wide association study identified chromosome 8 locus associated with medication-related osteonecrosis of the jaw. Clin Pharmacol Ther, 110: 1558-1569, 2021, PMID: 34390503
- (5) J. M. Collins and **D. Wang**. Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4\*1G and CYP3A metabolism. Pharmacogenetics and Genomics, 32:16-23, 2021, PMID: 34320606
- (6) J.M. Collins and **D. Wang**. Co-expression of drug metabolizing cytochrome P450 enzymes and estrogen receptor alpha (ESR1) In human liver: racial differences and the regulatory role of ESR1. Drug metabolism and Personalized Therapy, 36:205-214, 2021, PMID: 33823094. DOI: <https://doi.org/10.1515/dmpt-2020-0160>
- (7) J.M. Collins, Z. Huo and **D. Wang**. ESR1 ChIP-Seq identifies distinct ligand-free ESR1 genomic binding sites in human hepatocytes and liver tissue. Int. J. Mol. Sci. 22:1461, 2021. <https://doi.org/10.3390/ijms22031461>, PMID: 33540646
- (8) D. Chen, H. Lu, W. Sui, L. Li, J. Xu, T. Yang, S. Yang, P. Zheng, Y. Chen, J. Chen, W. Xue, Q. Li, Q. Zheng, D. Ye, W. Sadee, **D. Wang**, W. Qian, L. Lai, C. Li and L. Li. Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. The Pharmacogenomics Journal, 21(3): 376-389, 2021. Doi: 10.1038/s41397-021-00216-w. PMID: 33649515
- (9) G. Yang, J.M. Collins, R. Rafiee, S. Singh, T. Langaee, C.W. McDonough, L. S. Holliday, D. Wang, J. Lamba, Y.S. Kim, Gian A. Pelliccioni, M. Vasziiko, J.P. Kosa, B. Balla, P.A. Lakatos, J. Katz, J. Moreb, Y. Gong. SIRT1 gene SNP rs932658 is associated with medication-related osteonecrosis of the jaw. J Bone Miner Res. 36(2): 347-356, 2021, PMID: 32967053
- (10) C. Thomas, S. Mosley, S. Kim, K. Lingineni, N.E. Rouby, T. Langaee, Y. Gong, **D. Wang**, S. Schmidt, P. Binkley, D. Estores, K. Feng, H. Kim, M. Kinjo, Z. Li, L. Fang, A. Chapman, R. Cooper-Dehoff, J. Gums, I. Hamadeh, L. Zhao, S. Schmidt, R. Frye, J. Johnson and L. Cavallari. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores. CPT: Pharmacometrics & System Pharmacology. 9(12):678-685, 2020. PMID: 33067866
- (11) J. Li, N. Seligson, X. Zhang, J. Johnson, Z. Vangundy, **D. Wang**, M. Phelps, C. Hofmeister, W. Sadee and M.J. Poi. Association of ANRIL polymorphism with overall survival in adult patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation. Anticancer Research, 40(10): 5707-5713, 2020. PMID: 32988896
- (12) J.M. Collins and **D. Wang**. Cis-acting regulatory elements regulating CYP3A4 transcription in human liver. Pharmacogenetics and Genomics, 30:107-116, 2020, PMID: 32301865
- (13) A.K. Persaud, J. Li, J.A. Johnson, N. Seligson, D.W. Sborov, E. Duah, Y. K. Cho, **D. Wang**, M.A. Phelps, C.C Hofmeister, M.J. Poi. XRCC1-mediated DNA repair is associated with progression-

- free survival of multiple myeloma patients after autologous stem cell transplant. *Molecular Carcinogenesis* 58:2327-2339, 2019, PMID:31544312
- (14) J.A. Luzum, C. Ting, E. Peterson, H. Gui, T. Shugg, L. Li, W. Sadee, **D. Wang**, D.E. Lanfear. Association of cardiac-specific regulatory genetic variants for protein kinase C alpha with mortality in patients with heart failure. *Cardiovascular Drugs and Therapy*, 33:693-700, 2019, PMID: 31728800
- (15) **D. Wang**, R. Lu, G. Rempala and W. Sadee. Ligand-free estrogen receptor alpha (ESR1) as master regulator for the expression of CYP3A4 and other cytochrome P450 enzymes in the human liver. *Mol. Pharmacol.* 96:430-440, 2019, PMID: 31399483
- (16) J.W. Sun, J.M. Collins, D. Ling and **D. Wang**. Highly variable expression of ESR1 splice variants in human liver: implication in the liver gene expression regulation and inter-person variability in drug metabolism and liver related diseases. *Journal of Molecular and Genetic Medicine* 13:1000434, 2019, PMID: 32457812, PMCID: PMC7249510
- (17) J. Sun, S.R. Tung, **D. Wang**, J.P. Kitzmiller and S. Smith. A comparison of genetic sampling methodologies for candidate-gene analyses. *J. Translational Science*, 5(3):10.15761/JTS.1000306, 2019. PMID: 31749990, PMCID: PMC6867604
- (18) B. Ray, E. Ozcagli, W. Sadee and **D. Wang**. CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (\*2 allele): implications for CYP2D6 genotype panels. *Pharmacogenet Genomics* 29(2): 39-47, 2019, PMID: 30520769
- (19) J. Shi, X. Wang, H. Zhu, H. Jiang, **D. Wang**, A. Nesvizhskii and H.J. Zhu. Determining allele-specific protein expression (ASPE) using a novel quantitative concatamer based proteomics method. *J. Proteome Res.* 17(10): 3606-3612, 2018, PMID: 30141943
- (20) **D. Wang**, K. Hartmann, M. Seweryn and W. Sadee. Interactions between regulatory variants in CYP7A1 (Cholesterol 7 $\alpha$ -hydroxylase) promoter and enhancer regions regulate CYP7A1 expression. *Circ. Genom Precis Med.* 11(10): e002082, 2018, PMID: 30354296
- (21) R. Lu, **D. Wang**, G.A. Rempala. Estimation of sobol's sensitivity indices under generalized linear models. *Commun Stat. Theory Methods.* 47(21): 5163-5195, 2018, PMID: 30237653
- (22) L. Li, L. Zhang, P.F. Binkley, W. Sadee and **D. Wang**. Regulatory variants modulate protein kinase C alpha (PRKCA) gene expression in human heart. *Pharm Res.* 34:1648-1657, 2017. PMID: 28120175
- (23) J.K. Pinsonneault, J.T. Frater, B. Kompa, R. Mascarenhas, **D. Wang**, W. Sadee. Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits. *PLoS One* 12(6): e0179020, 2017, PMID: 28617822
- (24) E.S. Barrie, K. Hartmann, S.H. Lee, J.T. Frater, M. Seweryn, **D. Wang** and W. Sadee. The CHRNA5/CHRNA3/CHRNA4 nicotinic receptor regulome: genomic architecture, regulatory variants, and clinical associations. *Hum Mutat.* 38:112-119, 2017, PMID: 27758088
- (25) J.C. Sanford, X. Wang, J. Shi, E.S. Barrie, **D. Wang**, H.J. Zhu and W. Sadee. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus. *Pharmacogenetics and Genomics.* 26:197-207, 2016. PMID: 26871237, PMCID: PMC4821783
- (26) **D. Wang** and W. Sadee. CYP3A4 intronic SNP rs35599367 (CYP3A4\*22) alters RNA splicing. *Pharmacogenetics and Genomics.* 26:40-43, 2016, PMID: 26488616, PMCID: PMC4674354
- (27) A. Webb, A.C. Papp, A. Curtis, L.C. Newman, M. Pietrzak, M. Seweryn, S.K. Handelman, G.A. Rempala, **D. Wang**, E. Graziosa, R.F. Tyndale, C. Lerman, J.R. Kelsoe, D.C. Mash, W. Sadee. RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. *BMC Genomics* 16:990, 2015. PMID: 26597164, PMCID: PMC4657279
- (28) A. Suhy, K. Hartmann, A.C. Papp, **D. Wang** and W. Sadee. Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616. *Pharmacogenetics and Genomics* 25:394-401, 2015, PMID: 26061659, PMC4499003
- (29) R. Lu, R.M. Smith, M. Seweryn, **D. Wang**, K. Hartmann, A. Webb, W. Sadee and G.A. Rempala. Analyzing allele specific RNA expression using mixture models. *BMC Genomics* 16:566, 2015, PMID: 26231172, PMC4521363
- (30) R. Mascarenhas, M. Pietrzak, R.M. Smith, A. Webb, **D. Wang**, A.C. Papp, J.K. Pinsonneault, M. Seweryn, G. Rempala, W. Sadee. Allele selective transcriptome recruitment to polysomes



- primed for translation: protein-coding and noncoding RNAs, and RNA isoforms. *PLoS One*, 10:e0136798, 2015, PMID: 26331722, PMC4558023
- (31) S.K. Handelman, M. Seweryn, R.M. Smith, K. Hartmann, **D. Wang**, M. Pietrzak, A.D. Johnson, A. Kloczkowski and W. Sadee. Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait (eQTLs). *BMC Genomics* 16(suppl) 8: S8, doi: 10.1186/147-2164-16-S8-S8, 2015. PMID: 26111110, PMC4480832
- (32) K.A. Birdwell, B. Decker, J.M. Barbarino, J.F. Peterson, C.M. Stein, W. Sadee, **D. Wang**, A.A. Vinks, Y. He, J.J. Swen, J.S. Leeder, R.H. Van Schaik, K.E. Thummel, T.E. Klein, K.E. Caudle and I.A. MacPhee. Clinical Pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. *Clin. Pharmacol. Ther.* 98: 19-24, 2015. PMID: 25801146, PMC4481158
- (33) **D. Wang**, A.C Papp, X. Sun. Functional characterization of CYP2D6 enhancer polymorphisms. *Human Molecular Genetics*, 24:1556-1562, 2014. PMID: 25381333, PMC4381757
- (34) **D. Wang**, M.J Poi, X. Sun, A. Gaedigk, J.S. Leeder, W. Sadee. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. *Human Molecular Genetics*, 23(1): 268-278, 2014. PMID: 23985325, PMC3857955
- (35) M.A. Phelps, T.E. Stinchcombe, J.S. Blachy, W. Zhao, L.J. Schaaf, S.L. Starrett, L. Wei, M. Poi, **D. Wang**, A.Papp, J. Aimiuwu, Y. Gao, J. Li, G.A. Otterson, W.J. Hicks, M.A. Socinski, M.A. Villalona-Calero. Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses. *Clin. Pharmacol. Ther.* 96:182-191, 2014. PMID:24781527, PMC4180036
- (36) A. S. Gordon, H.K. Tabor, A.D Johnson, B.M. Snively, T.L. Assimes, P.L. Auer, J.P.A. Ioannidis, U. Peters, J.G. Robinson, L.E. Sucheston, **D. Wang**, N.Sotoodehnia, J.I. Rotter, B.M. Psaty, R.D. Jackson, D.M. Herrington, C.J.O'Donnell, A.P. Reiner, S. S. Rich, M.J. Reider, M.J. Bamshad, D.A. Nickerson. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. *Human Molecular Genetics*, 23(8):1957-1963, 2014. PMID: 24282029, PMC3959810
- (37) J. C. Sanford, W Sadee and **D. Wang**. Regulatory polymorphisms in CYP2C19\*17 affecting hepatic expression. *Drug Metabolism and Drug Interactions*, 28(1): 23-30, 2013. PMID:23412869, PMCID: PMC3755489
- (38) L.H. Cavallari, D. Vaynshteyn, K.M. Freeman, **D.Wang**, M.A. Perera, H. Takahashi, K. Drozda, S.R. Patel, H. Jeong. CYP2C9 promoter region SNPs linked to the R150H polymorphism are functional suggesting a new CYP2C9\*8 designation. *Pharmacogenetics and Genomics*, 23(4): 228-231, 2013. PMID:23376925, PMC3629689
- (39) **D. Wang** and W. Sadee. The making of a CYP3A biomarker panel for guiding drug therapy. *Journal of Personalized Medicine (Review)*, 2:175-191, 2012. PMID: 24466438, PMC3901424
- (40) J.P Kitzmiller, D.M. Sullivan, M.A. Phelps, **D. Wang**, W. Sadee. CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. *Drug Metabolism and Drug Interactions*, 28(1):59-63, 2012. PMID:23314529, PMC3681953
- (41) **D. Wang**, A. Curtis, A.C. Papp, S.L. Koletar and M.F. Para. Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. *BMC Medical Genomics* 5:32, 2012. PMID 22824134, PMC3418550
- (42) S. Coon, **D. Wang** and L. Wu. Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV-1 in Europeans and African Americans. *AIDS Res Hum Retroviruses*, Apr 24, 2012 online, PMID 22530776, PMC3505062
- (43) A.C. Papp, J.K. Pinsonneault, **D. Wang**, L.C. Newman, Y. Gong, J.A. Johnson, C.J. Pepine, M. Kumari, A.D. Hingorani, P.J. Talmud, S. Shah, S.E. Humphries, W. Sadee. Cholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. *PloSOne* 7(3);e31930, 2012, PMID 22403620, PMC3293889
- (44) **D. Wang**, X. Sun, Y. Gong, B.E. Gawronski, T.Y. Langae, M.H. Shahin, S.I. Khalifa, J.A. Johnson. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. *Drug Metab, Dispos.* 40(5): 884-891, 2012, PMID 22289258, PMC3336790
- (45) **D. Wang**, M.F. Para, S.L. Koletar and W. Sadee. Human N-acetyltransferase 1 \*10 and \*11 alleles increase protein expression through distinct mechanisms and associate with

- sulfamethoxazole-induced hypersensitivity. *Pharmacogenet Genomics*, 21(10): 652-664, 2011, PMID 21878835, PMC3172334
- (46)W. Sadee, **D. Wang**, A.C Papp, J.K Pinsonneault, R.M Smith, R.A Moyer, A.D Johnson. Pharmacogenomics of the RNA world: Structural RNA polymorphisms in drug therapy. *Clin Pharmacol Ther* 89(3): 355-365, 2011. PMID 21289622, PMC3251919
- (47)R.A. Moyer, **D. Wang**, A.C. Papp, R.M. Smith, L. Duque, D.C. Mash and W. Sadee. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. *Neuropsychopharmacology* 36(4): 753-762, 2011. PMID 21150907, PMC3055737
- (48)R.M., Smith, H. Alachkar, A.C. Papp, **D. Wang**, D.C. Mash, J. Wang, L.J. Bierut and W. Sadee. Nicotinic alpha receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. *Eur. J. Human Gen.* 19 (1): 76-83, 2011. PMID 20700147, PMC2995013
- (49)**D. Wang**, Y. Guo, S.A. Wrighton, G.E. Cooke and W. Sadee. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *The Pharmacogenomics J.* 11(4):274-286, 2011, PMID 20386561, PMC3248744
- (50)H. Wang, M. Karikomi, S. Naidu, R. Rajmohan, E. Caserta, H.Z. Chen, M. Rawahneh, J. Moffitt, J.A. Stephens, S.S. Fernandez, M. Weinstein, **D. Wang**, W. Sadee, K. La Perle, P. Stromberg, T.T. Rosol, C. Eng, M.C. Ostrowski, G. Leone. Allele-specific tumor spectrum in pten knockin mice. *PNAS* 107(11): 5142-5147, 2010. PMID 20194734, PMC2841921
- (51)A.C. Beitelshes, H. Navare, **D. Wang**, Y. Gong, J. Wessel, J.I. Moss, T.Y. Langaee. R.M. Cooper-Dehoff, W. Sadee, C.J. Pepine, N.J. Schork and J.A. Johnson. CACNA1C gene polymorphisms, cardiovascular disease outcomes and treatment response. *Cir Cardiovasc. Genet.* 2:362-370, 2009. PMID 20031608, PMC2761685
- (52)A. Bertolino, L. Fazio, G. Caforio, G. Blasi, A. Rampino, R. Romano, AD. Giorgio, P. Taurisano, A. Papp, J. Pinsonneault, **D. Wang**, M. Nardini, T. Popolizio and W. Sadee. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. *Brain*, 132:417-422, 2009. PMID 18829695, PMC2640212
- (53)AD. Johnson, Y. Gong, **D. Wang**, TY. Langaee, J. Shin, RM. Cooper-Dehoff, NJ. Schork, P. Binkley, CJ. Pepine,JA. Johnson, W. Sadee. Promoter polymorphisms in ACE (Agiotension I converting enzyme) associated with clinical outcomes in hypertension. *Clinical Pharmacology and Therapeutics*, 85:36-44, 2009. PMID 18946466, PMC2709290
- (54)A.D. Johnson, Y. Zhang, A.C. Papp, J.K. Pinsonneault, J.E. Lim, D. Saffen, Z. Dai, **D Wang** and W. Sadee. Polymorphisms affecting gene transcription and mRNA processing on pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. *Pharmacogenetics and Genomics.* 18: 781-791, 2008 PMID 18698231, PMC2779843
- (55)**D. Wang**, H. Chen, K. M. Momary, L. H. Cavallari, J. A. Johnson and W. Sadee. Regulatory polymorphism in vitamin K epoxide reductase subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. *Blood* 112: 1013-1021, 2008. PMID 18523153, PMC2515137
- (56)Z. Dai\*, A.C. Papp\*, **D. Wang\***, H. Hampel and W. Sadee. Genotyping panel for assessing cancer risk and response to chemotherapy. *BMC Medical Genomics* 1:24, 2008 (\* equal contribution). PMID 18547414, PMC2442111
- (57)Y. Zhang, A. Bertolino, L. Fazio, G. Blast, A. Rampino, R. Romano, M.L.T. Lee, T. Xiao, A. Papp, **D. Wang** and W. Sadee. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. *Proc. Natl. Acad. Sci. USA* 104:20552-20557, 2007 PMID 18077373, PMC2154469
- (58)A.L. Beitelshes, Y. Gong, **D. Wang**, N.J. Schork, R.M. Cooper-DeHoff, T.Y. Langaee, M.D. Shriver, W. Sadee, H.J. Knot, C.J. Pepine and J.A. Johnson. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the International Verapamil SR/Trandolapril Study (INVEST). *Pharmacogenetics and Genomics.* 17:719-729, 2007 PMID 17700361, PMC2713584
- (59)**D. Wang**, X. Sun and W. Sadée. Different effects of opioid antagonists on m- d- and k- opioid receptor with and without agonist pretreatment. *J.P.E.T.* 321: 544-552, 2007. PMID 17267582
- (60)**D. Wang** and W. Sadée. Searching for polymorphisms that affect gene expression and mRNA processing: Example MDR1 (ABCB1) (review). *AAPS J.* 8(3): E515-E520, 2006. PMID 17025270, PMC2761059

- (61) **D. Wang**, A.C Papp, P.F. Binkley, J.A. Johnson and W. Sadée. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C (CACNA1C) in human heart tissues. *Pharmacogenetics and Genomics*, 16: 735-745, 2006. PMID: 17001293
- (62) J.L Lucas, **D. Wang** and W. Sadée. Calmodulin binding to peptides derived from the i3 loop of muscarinic receptors. *Pharmaceutical Research*, 23:647-653, 2006, PMID: 16552497
- (63) **D. Wang**, D.J. Andrew, A.C. Papp, D.L. Kroetz and W. Sadée. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. *Pharmacogenetics and Genomics*, 15:693-704, 2005, PMID 16141795
- (64) Y. Zhang, **D. Wang**, J.D. Andrew, A.C. Papp and W. Sadée. Allelic expression imbalance of mu opioid receptor (OPRM1) caused by variant A118G. *J. Biol. Chem.* 280: 32618-32624, 2005, PMID 16046395
- (65) **D. Wang**, X. Sun, L. Bohn and W. Sadée. Opioid receptor homo- and hetero-dimerization in living cells by quantitative bioluminescence resonance energy transfer. *Molecular Pharmacology*, 67:2173-2184, 2005, PMID: 15778451
- (66) A.D. Johnson, **D. Wang** and W. Sadée. Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics (review). *Pharmacology and Therapeutics*, 106 (1): 19-38, 2005, PMID: 15781120
- (67) K.M Raehal, J.J. Lowery, C.M. Bhamidipati, R.M. Paolino, **D. Wang**, W. Sadée and E.J. Bilsky. In vivo characterization of 6b-naltrexol, an opioid ligand with less inverse agonist activity compared to naltrexone and naloxone in opioid dependent mice. *J. Pharmacol. Exp. Ther.* 311:1-13, 2005. PMID: 15716384
- (68) Y. Zhang, **D. Wang** and W. Sadée. Calmodulin interacting with peptides from G-protein coupled receptors measured with S-Tag labeling. *Biochem. Biophys. Res. Communica.* 333 (2): 390-395, 2005. PMID: 15950946
- (69) W. Sadée, **D. Wang** and E.J Bilsky. Basal opioid receptor activity, neutral antagonists and therapeutic opportunities (minireview). *Life Science* 76: 1427-1437, 2004, PMID: 15680308
- (70) **D. Wang**, K. M. Raehal, E.T. Lin, J. Lowery, B. Kiffer, E. J. Bilsky and W. Sadée. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. *J. Pharmacol. Exp. Ther.* 308: 512-520, 2004, PMID: 14600246
- (71) K.Lin\*, **D. Wang**\* and W. Sadée. Serum response factor (SRF) activation by muscarinic receptors: novel pathway specific to hM1 subtype involving calmodulin, calcineurin and Pyk2. *J. Biol. Chem.* 277: 40789-40798, 2002. \* Equally contributed. PMID: 12200418
- (72) J.M. Quillan, C. Song, K. Carlson, **D. Wang** and W. Sadée. Differential effect of mu opioid receptor (MOR) ligands on Ca<sup>2+</sup> signaling. *J. Pharmacol. Exp. Ther.* 302: 1002-1012, 2002. PMID: 12183657
- (73) M.M Belcheva, M. Szucs, **D. Wang**, W. Sadée and C.J. Coscia. Mu opioid receptor-mediated ERK-activation involves calmodulin-dependent EGF receptor transactivation. *J. Biol. Chem.* 276: 33847-33853, 2001, PMID: 11457825
- (74) **D. Wang**, M.J. Quillan and W. Sadée. Single-nucleotide polymorphisms in the human mu opioid receptor gene alter calmodulin and/or G protein coupling. *J. Biol. Chem.* 276: 34624-34630, 2001, PMID: 11457836
- (75) W. Sadée, E. Hoeg, J.L. Lucas and **D. Wang**. Genetic variations in human G protein-coupled receptors: Implication for drug therapy (Review). *AAPS PharmSci.* 3(3), article 22, 2001 ([http://www.pharmsci.org/scientificjournals/pharmsci/journal/o1\\_22.html](http://www.pharmsci.org/scientificjournals/pharmsci/journal/o1_22.html)), PMID : 11741273
- (76) **D. Wang**, K.M Raehal, E.J. Bilsky and W. Sadée. Inverse agonists and neutral antagonists of mu opioid receptor—evidence of elevated basal signal activity of MOR after morphine treatment as a mechanism for opioid dependence and withdrawal. *J. Neurochem* 77 : 1590-1600, 2001, PMID: 11413242
- (77) **D. Wang**, Christopher K. Surrat and Wolfgang Sadée. Calmodulin regulation of basal and agonist-stimulated G protein coupling by the mu opioid receptor in morphine pretreatment cells. *J. Neurochem.* 75:763-771, 2000, PMID: 10899953
- (78) N.T. Burford, **D. Wang** and W. Sadée. G-protein coupling to mu opioid receptors: elevated basal signaling activity. *Biochem. J.* 348: 531-537, 2000, PMID: 10839983
- (79) **D. Wang**, L.M. Tolbert, K.W. Carlson and W. Sadée. Nuclear Ca<sup>++</sup>/calmodulin signaling pathway activated by mu opioid receptor. *J. Neurochem.* 74: 1418-1425, 2000, PMID: 10737597

- (80) D. Choi, **D. Wang**, L.M. Tolbert and W. Sadée. Basal signaling activity of dopamine D2L receptors demonstrated with an inducible mammalian expression system. *J. Neurosci. Methods.* 94: 217-225, 2000, PMID: 10661841
- (81) **D. Wang**, W. Sadée and J.M. Quillan. Calmodulin binding to a G protein coupling domain in the mu opioid receptor. *J. Biol. Chem.* 274: 22081-22088, 1999, PMID: 10419536
- (82) Z. Wang, E.J. Bilsky, **D. Wang**, F. Porreca and W. Sadée. 3-Isobutyl-1-methylxanthine inhibits basal mu opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. *Eur. J. Pharmacol.* 371: 1-9, 1999, PMID: 10355588
- (83) **D. Wang** and B. Qin. Regulatory effect of dihydroetorphine on rat mu opioid receptor gene expression after chronic morphine treatment. *Chinese J Pharmacol. Toxicol.* 10(4): 247-250, 1996,
- (84) **D. Wang** and B. Qin. The binding of <sup>3</sup>H-dihydroetorphine to rat brain opioid receptors. *Acta. Pharmacol. Sinica.* 17(3): 281-283, 1996, PMID: 9812759
- (85) **D. Wang** and B. Qin. The progress of the study of opioid receptors (review). *Oversea Medical Sciences Pharmacology Section.* 22(6): 321-326, 1995
- (86) **D. Wang**, X. Lu and B. Qin. 1994. Dihydroetorphine is a mu receptor selective ligand. *J. Pharm. Pharmacol.* 47:669-673, 1995, PMID: 8583370
- (87) **D. Wang**, Y. Liu and B. Qin. Experimental therapeutic effect of dihydroetorphine on morphine dependent rats and monkeys. *Chinese J. Pharmacol. Toxicol.* 6: 36-40, 1992
- (88) **D. Wang** and B. Qin. Effect of dihydroetorphine on contraction response of guinea pig ileum, mouse and rabbit deferens induced by electric field stimulation in vitro. *Acta. Pharmacol. Sinica.* 12: 420-422, 1991, PMID: 1687907
- (89) **D. Wang**, M. Huang and B. Qin. Binding characteristics of dihydroetorphine to opioid receptors in rat brain. *Chinese J. Pharmacol. Toxicol.* 6:161-168, 1991

### Abstracts

- (1) **D. Wang**, D. Xu and Z. Yang. Coexistence of  $\beta_1$  and  $\beta_2$  adrenoceptor subtypes in pig coronary artery. 5<sup>th</sup> Southeast Asian and Western Pacific Regional Meeting of Pharmacologists. Beijing, China, August, 1988
- (2) **D. Wang** and B. Qin. Detoxification effect of dihydroetorphine on rats and monkeys. 4<sup>th</sup> Chinese Pharmacology Meeting, Shanghai, China, October, 1990.
- (3) **D. Wang**, Y. Liu and B. Qin. The binding characteristics of dihydroetorphine on mu opioid receptor. 6<sup>th</sup> Chinese Biochemistry Meeting, Chongqing, China, March, 1990.
- (4) B. Qin, **D. Wang** and M. Huang. The application of dihydroetorphine to detoxification of heroin addicts. 25<sup>th</sup> International Narcotic Research Conference. Sweden, August, 1994.
- (5) M. Huang, **D. Wang** and B. Qin. Dihydroetorphine, a potent opioid with low dependent potential. 25<sup>th</sup> International Narcotic Research Conference. Sweden, August, 1994.
- (6) **D. Wang**, N.T. Burford and W. Sadee. Signal transduction by mu opioid receptors after morphine treatment. Role of Ca<sup>++</sup> in the inverse naloxone effect on cAMP. 28<sup>th</sup> International Narcotic Research Conference. Hong Kong August, 1997.
- (7) N.T. Burford, **D. Wang** and W. Sadee. Coupling of mu opioid receptor to multiple G proteins. Enhanced activity at G<sub>i3</sub> and agonistic properties of naloxone. 28<sup>th</sup> International Narcotic Research Conference. Hong Kong, August, 1997.
- (8) **D. Wang**, N.T. Burford and W. Sadee. Mu opioid receptor-calmodulin interactions. 29<sup>th</sup> International Narcotic Research Conference. Garmisch Partenkirchen, German, July, 1998.
- (9) **D. Wang**, J.M. Quillan, N.T. Burford and W. Sadee. Direct interaction between calmodulin and opioid receptor. A possible signaling pathway. 28<sup>th</sup> Annual Meeting. Los Angeles, November, 1998.
- (10) **D. Wang**, J.M. Quillan and W. Sadee. Morphine translocates calmodulin to cell nucleus and regulates the phosphorylation of cAMP responsive element binding protein. 30<sup>th</sup> International Narcotic Research Conference. New York, July, 1999.
- (11) K.M. Raehal, **D. Wang**, W. Sadee and E.J. Bilsky. Regulation of CREB phosphorylation in mouse spinal cord: possible role in opioid tolerance and physical dependence. American Society for Pharmacology and Experimental Therapeutics, Boston, June, 2000.

- (12) M. Belcheva, M. Szucs, **D. Wang**, W. Sadee and C. Coscia. Ca<sup>++</sup>/CaM binding to mu opioid receptor and its role in opioid activation of ERK. 31<sup>st</sup> International Narcotic Research Conference, Seattle, July, 2000.
- (13) **D. Wang**, J.M. Quillan and W. Sadee. Basal G protein coupling and calmodulin binding of human mu opioid receptor is altered by single nucleotide polymorphisms. American Association of Pharmaceutical Scientists Annual Meeting, Denver, Colorado, October, 2001.
- (14) **D. Wang**, E.J. Bilsky, E.T. Lin, B. Kieffer and W. Sadee. Regulation of basal signaling activity of mu opioid receptor in mouse brain and its role in narcotic dependence. 33<sup>rd</sup> International Narcotics Research Conference, July 9-14, 2002.
- (15) J. Blair, **D. Wang**, K. M. Raehal, W. Sadee, E.J. Bilsky. 6-beta-Naltrexol, an opioid neutral antagonist, precipitates less severe withdrawal compared to the inverse agonist naltrexone: dose-response and time course studies. 33<sup>rd</sup> International Narcotics Research Conference, July 9-14, 2002.
- (16) **D. Wang**, K.M. Raehal, B. Kieffer, E.J. Bilsky and W. Sadee. Basal signaling activity of mu opioid receptor and its role in narcotic dependence. Hunt-Curtis Symposium on Translational Neuroscience, Columbus, Ohio, September 18-20, 2002
- (17) J. Lucas, **D. Wang** and W. Sadee. Interaction between calmodulin and i3 loop of G-protein coupled receptors. Hunt-Curtis Symposium on Translational Neuroscience, Columbus, Ohio, September 18-20, 2002
- (18) **D. Wang**, E.J. Bilsky, E.T. Lin, B. Kieffer and W. Sadee. Long-term regulation of basal signaling activity of mu opioid receptor in vivo. Society for Neuroscience 32<sup>nd</sup> Annual Meeting, Orlando, November 2-7, 2002.
- (19) **D. Wang**, X. Sun and W. Sadee. Opioid receptor homo- and hetero-dimerization in living cells by quantitative bioluminescence energy transfer. AAPS-NIDA Symposium. Frontier in Science: Drug Addiction-From Basic Research to Therapies. NIH, Baltimore, MD, Sep. 9-11, 2004
- (20) M.A. Phelps, **D. Wang**, J.E. Aimuwn, S.L. Starrett, A.C. Papp, A. A. Ghany, W. J. Hicks, K.V. Kosuri, G.A. Otlerson, M.A. Socinski, T.E. Stinchcombe, W. Zhao, L.T. Schaaf, S.H. Barsky, K.K. Chan, W. Sadee, M.A. Villalona-Calero. Erlotinib in African Americans with lung cancer: A prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization. American Association for Cancer Research Annual Meeting (AARC), San Diego, California, April, 2009
- (21) J.A. Sipos, **D. Wang**, L. Wei, R. Kloos, M. Ringel, M. Shah. VEGF polymorphisms predict adverse events in patients taking sorafenib for refractory thyroid cancer. International Thyroid Congress: Genetics and proteomics of thyroid diseases. Paris, September, 2010
- (22) **D. Wang**, M.F. Para, S.L. Koletar and W. Sadee. Common alleles in human N-acetyltransferase 1 (NAT1 \*10 and \*11) increase enzyme activity via distinct mechanisms and associate with sulfamethoxazole induced hypersensitivity. Experimental Biology Meeting 2011, Washington D.C. April 9-13, 2011
- (23) **D. Wang**, X. Sun. Regulatory polymorphism in promoter region of CYP2C9 affects mRNA expression in human livers. The 17<sup>th</sup> North American Regional ISSX Meeting, Atlanta, Georgia, Oct 16-20, 2011
- (24) **D. Wang**, M.J. Poi, A. Gaedigk, J.S. Leeder and W. Sadee. CYP2D6 expression is regulated by polymorphisms that affecting splicing and transcription: New biomarker for CYP2D6 activity. Experimental Biology, Boston, October, 2013
- (25) J.C. Sanford, Y. Guo, W. Sadee and **D. Wang**. Population specific regulatory polymorphisms acting on CYP2C19 in human liver. Great Lakes Metabolism Meeting, October 9-10, 2013
- (26) **D. Wang**, R. Lu, G. Rempala and W. Sadee. CYP3A interactome and the causes of CYP3A variability. PGRN-ASHG Symposium. Vancouver, Canada, October, 2016
- (27) **D. Wang**, R. Lu, G. Rempala and W. Sadee. Regulatory network of transcription factors determining CYP3A4 expression identified with mathematical modeling and CRISPR-mediated genome editing. American Society of Human Genetics, San Diego, California, October, 2018
- (28) J. Collins, D. Ling and **D. Wang**. Genome-wide unliganded estrogen receptor alpha (ESR1) binding in human liver. American Society of Human Genetics, Houston, Texas, October, 2019
- (29) **D. Wang**, R. Lu, G. Rempala and W. Sadee. Ligand-free estrogen receptor alpha (ESR1) as master regulator for the expression of CYP3A4 and other cytochrome P450s (CYPs) in human liver. 12<sup>th</sup> International ISSX meeting, Portland, Oregon, July, 2019

- (30)**D. Wang**. Regulatory polymorphisms in drug metabolizing enzymes and their clinical relevance. Virtual online conference on Pharmaceutics, Pharmacology and Drug Delivery Systems, September, 10, 2020
- (31)J. Collins and **D. Wang**. Chromatin interactions occurring within CYP3A locus. American Society of Human Genetics. Virtual online conference, October, 27-30, 2020
- (32)J. Collins and **D. Wang**. Regulation of CYP3A genes by a novel lncRNA: a potential mechanism underlying CYP3A5\*1G. Pharmacogenomics Research Network Symposium virtual online meeting, October 26, 2020
- (33)J. Collins and **D. Wang**. Mapping chromatin interaction within CYP3A locus. American Society of Human Genetics. Virtual online meeting, October 26, 2021
- (34)J. Collins and **D. Wang**. Regulation of the CYP3A genes by a distal enhancer and regulatory variants. Pharmacogenomics Research Network Symposium virtual online meeting, October 26, 2021
- (35)J. Collins and **D. Wang**. A novel lncRNA regulates CYP3A4 and CYP3A5 expression: mechanism underlying CYP3A4\*1G. ASCPT 2021 Annual Meeting, online virtual meeting, March, 2021